Adhesions are not preventable by surgical technique alone.  Adhesions develop routinely following surgery, and have been reported at second-look surgery to occur in up to 93% of patients (n=210) following laparotomy2. SEPRAFILM Adhesion Barrier is an adhesion barrier that reduces the incidence, extent and severity of adhesions following abdominopelvic surgery1,2.

Adhesions are not preventable by surgical technique alone

Adhesions develop routinely following both open and laparoscopic abdominal surgery, and have been reported at second-look surgery to occur in up to 93% of patients (n=210) following laparotomy2.

SEPRAFILM efficacy in abdominal surgery

In a randomized, prospective, double-blinded, multicenter clinical study involving 183 patients [175 evaluable] with ulcerative colitis and familiar polyposis undergoing 2-stage intestinal resection, more than half of the patients treated with SEPRAFILM were adhesion-free at 12 weeks compared to 6% of untreated patients2.

SEPRAFILM efficacy in pelvic surgery

In a prospective, randomized, blinded, multicenter clinical study involving 127 patients undergoing gynecologic surgery, SEPRAFILM reduced the mean number of sites adherent to the anterior uterine surface following myomectomy compared with untreated patients. SEPRAFILM also significantly reduced the extent and severity of adhesions in patients undergoing uterine myomectomy compared with untreated patients3.

Protection When It Matters Most

Separates tissues for up to 7 days - the critical tissue healing period1,2

A Proven Legacy

More than 4 million patients have received SEPRAFILM in clinical use worldwide. Robust clinical data (n=2,133) across five clinical studies have demonstrated the safety and efficacy of SEPRAFILM Adhesion Barrier. 2-6

Bioresorbable and Synthetic

SEPRAFILM is composed of sodium hyaluronate and carboxymethylcellulose (HA/CMC)

¿Estás interesado en información adicional sobre SEPRAFILM?

Seprafilm Adhesion Barrier Indications

Seprafilm is intended as an adjunct in abdominal and pelvic surgery for reducing the incidence, extent and severity of postoperative adhesions at the site of placement, and to reduce adhesive small bowel obstruction when placed in the abdomen.


Seprafilm is contraindicated in patients with a history of hypersensitivity to Seprafilm and/or to any component of Seprafilm.

Important Risk Information

  • Seprafilm is not recommended to be wrapped directly around a fresh anastomotic suture or staple line of the intestine. Clinical trial data on Seprafilm indicate that such use may result in an increased risk of anastomotic leak-related events (fistula, abscess, leak, sepsis and peritonitis). The incidence of these events was not affected when Seprafilm was placed elsewhere in the abdomen.
  • In patients undergoing surgery for ovarian, primary peritoneal or fallopian tube malignancies, Seprafilm use has been reported as having an increased risk of intraabdominal fluid collection and/or abscess, particularly when extensive debulking surgery was required.
  • No controlled clinical studies have been conducted in patients with active infections.
  • Foreign body reaction may occur, as with any implanted material and most surgical adjuncts, but have been rarely reported during clinical use.
  • Seprafilm has limited controlled clinical trial information in patients with abdominopelvic malignancy.

No pre-clinical reproductive studies have been conducted.  No clinical studies have been conducted in women who become pregnant in the first month after application of Seprafilm. Therefore, avoiding pregnancy during the first complete menstrual cycle after the use of Seprafilm should be considered.

SEPRAFILM Full Instructions For Use

CE 2797